Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Crescent appoints ex-Trinity chief Brendan Farrell CEO

This article was originally published in Clinica

Executive Summary

Irish osteoporosis detection specialist Crescent Diagnostics has appointed Brendan Farrell CEO. Mr Farrell most recently headed up EnBio, which specialises in surface modification technology for the medical and non-medical industries; before this, he was president and CEO of Irish diagnostics firm Trinity Biotech from 1994 until 2008. Dublin-based Crescent is developing a test for osteoporosis called BQT that analyses chemical bonds in a small toenail clipping, which has been shown to predict the future risk of hip fracture. The company is about to begin a Series B funding round through which it hopes to raise €5m ($6.6m) to accelerate the commercialisation of BQT. It is currently planning a pivotal study to support CE marking and US FDA approval. Mr Farrell replaces former Crescent CEO Ernest Poku, who left the company due to family commitments.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts